Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21 Saturday, May 22, 2021 12:20PM IST (6:50AM GMT)
New analyses from pivotal BAVENCIO ® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma New data from VISION study of TEPMETKO ® show association between liquid biopsy-identified biomarker and clinical response in METex14 skipping NSCLC, supporting liquid biopsy as a means for monitoring treatment response TEPMETKO Oral presentations from independent studies reinforce the position of ERBITUX ® in 1L RAS wt mCRC and as backbone of treatment in SCCHN